Rockefeller Capital Management
VYNE icon

Rockefeller Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Rockefeller Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4
Closed – – 3856
2022
Q4 		$0 Sell
4
-72
-95% -$288 ﹤0.01% 4242
2022
Q3 		$0 Hold
76
– – ﹤0.01% 4418
2022
Q2 		$0 Buy
76
+1
+1% +$8 ﹤0.01% 4417
2022
Q1 		$0 Buy
75
+2
+3% +$24 ﹤0.01% 4081
2021
Q4 		$1K Hold
73
– – ﹤0.01% 3703
2021
Q3 		$1K Buy
73
+1
+1% +$39 ﹤0.01% 3628
2021
Q2 		$4K Buy
+72
New +$5.7K ﹤0.01% 3116
2020
Q2 		– Sell
-110
Closed -$21K – 2700
2020
Q1 		$21K Hold
110
– – ﹤0.01% 1507
2019
Q4 		$37K Hold
110
– – ﹤0.01% 1229
2019
Q3 		$36K Buy
+110
New +$35.5K ﹤0.01% 1072

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Rockefeller Capital Management's VYNE Position: Q1 2023 in Review

Rockefeller Capital Management sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 4 shares.

Rockefeller Capital Management first reported a position in VYNE in Q3 2019 and held it in 10 quarters. The position peaked at $37K in Q4 2019. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

  • Rockefeller Capital Management reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 4 VYNE Therapeutics shares in Q1 2023.
  • Rockefeller Capital Management first reported a position in VYNE Therapeutics in Q3 2019 and held it in 10 quarters.
  • Rockefeller Capital Management's VYNE Therapeutics position peaked at $37K in Q4 2019.
  • 23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.